Envista (NYSE:NVST) Earns Hold Rating from Analysts at Citigroup

Citigroup started coverage on shares of Envista (NYSE:NVST) in a research note released on Wednesday, Marketbeat reports. The brokerage issued a hold rating and a $29.00 price objective on the stock.

Several other equities analysts have also recently issued reports on NVST. Mizuho raised their price target on Envista from $24.00 to $27.00 and gave the company a “neutral” rating in a report on Tuesday, February 10th. Weiss Ratings upgraded shares of Envista from a “sell (d)” rating to a “hold (c-)” rating in a research report on Tuesday, February 17th. Morgan Stanley set a $19.00 target price on shares of Envista in a research note on Friday, February 6th. JPMorgan Chase & Co. boosted their price target on shares of Envista from $22.00 to $26.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Finally, Zacks Research downgraded shares of Envista from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Seven research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $27.69.

Envista Stock Performance

NVST stock opened at $27.81 on Wednesday. The company has a 50 day moving average price of $27.14 and a 200 day moving average price of $23.46. Envista has a fifty-two week low of $14.72 and a fifty-two week high of $30.42. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.38 and a quick ratio of 2.04. The stock has a market capitalization of $4.53 billion, a PE ratio of 99.32, a price-to-earnings-growth ratio of 1.84 and a beta of 0.98.

Envista (NYSE:NVST) last announced its quarterly earnings data on Thursday, February 5th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.06. Envista had a return on equity of 6.54% and a net margin of 1.73%.Envista’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same period last year, the business posted $0.24 EPS. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Analysts forecast that Envista will post 1 EPS for the current year.

Insiders Place Their Bets

In other Envista news, SVP Mischa Reis sold 9,675 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $30.00, for a total transaction of $290,250.00. Following the transaction, the senior vice president owned 32,382 shares in the company, valued at approximately $971,460. This trade represents a 23.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.66% of the company’s stock.

Institutional Trading of Envista

Hedge funds have recently modified their holdings of the company. Millennium Management LLC boosted its stake in Envista by 1,442.7% during the 4th quarter. Millennium Management LLC now owns 2,420,615 shares of the company’s stock worth $52,552,000 after acquiring an additional 2,263,712 shares during the last quarter. Holocene Advisors LP bought a new stake in Envista in the second quarter valued at approximately $43,936,000. Norges Bank acquired a new stake in Envista in the fourth quarter worth $45,113,000. Alliancebernstein L.P. raised its holdings in Envista by 34.0% in the second quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock worth $119,164,000 after purchasing an additional 1,547,656 shares during the period. Finally, Freestone Grove Partners LP bought a new position in shares of Envista during the fourth quarter worth $29,046,000.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.